company background image
SAN

Sanofi ENXTPA:SAN Stock Report

Last Price

€84.75

Market Cap

€106.1b

7D

-12.0%

1Y

-3.0%

Updated

11 Aug, 2022

Data

Company Financials +
SAN fundamental analysis
Snowflake Score
Valuation6/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends5/6

SAN Stock Overview

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.

Sanofi Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sanofi
Historical stock prices
Current Share Price€84.75
52 Week High€106.66
52 Week Low€76.45
Beta0.36
1 Month Change-15.30%
3 Month Change-15.07%
1 Year Change-2.95%
3 Year Change13.26%
5 Year Change2.41%
Change since IPO103.73%

Recent News & Updates

Shareholder Returns

SANFR PharmaceuticalsFR Market
7D-12.0%-10.6%0.3%
1Y-3.0%-2.1%-6.3%

Return vs Industry: SAN underperformed the French Pharmaceuticals industry which returned 1.8% over the past year.

Return vs Market: SAN exceeded the French Market which returned -6.3% over the past year.

Price Volatility

Is SAN's price volatile compared to industry and market?
SAN volatility
SAN Average Weekly Movement3.9%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement5.0%
10% most volatile stocks in FR Market9.0%
10% least volatile stocks in FR Market2.8%

Stable Share Price: SAN is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: SAN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
197395,442Paul Hudsonhttps://www.sanofi.com

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

Sanofi Fundamentals Summary

How do Sanofi's earnings and revenue compare to its market cap?
SAN fundamental statistics
Market Cap€106.11b
Earnings (TTM)€6.64b
Revenue (TTM)€42.04b

16.0x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SAN income statement (TTM)
Revenue€42.04b
Cost of Revenue€12.84b
Gross Profit€29.20b
Other Expenses€22.56b
Earnings€6.64b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 28, 2022

Earnings per share (EPS)5.31
Gross Margin69.46%
Net Profit Margin15.80%
Debt/Equity Ratio26.7%

How did SAN perform over the long term?

See historical performance and comparison

Dividends

3.9%

Current Dividend Yield

63%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is SAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SAN?

Other financial metrics that can be useful for relative valuation.

SAN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.9x
Enterprise Value/EBITDA10x
PEG Ratio1.7x

Price to Earnings Ratio vs Peers

How does SAN's PE Ratio compare to its peers?

SAN PE Ratio vs Peers
The above table shows the PE ratio for SAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average22.6x
IPN Ipsen
10.9x-1.9%€8.0b
VIRP Virbac
27.7x9.8%€3.1b
VETO Vetoquinol
23x5.7%€1.4b
BOI Boiron
28.8x18.8%€821.5m
SAN Sanofi
16x9.5%€106.1b

Price-To-Earnings vs Peers: SAN is good value based on its Price-To-Earnings Ratio (16x) compared to the peer average (22.6x).


Price to Earnings Ratio vs Industry

How does SAN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Earnings vs Industry: SAN is good value based on its Price-To-Earnings Ratio (16x) compared to the French Pharmaceuticals industry average (23.3x)


Price to Earnings Ratio vs Fair Ratio

What is SAN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SAN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16x
Fair PE Ratio29x

Price-To-Earnings vs Fair Ratio: SAN is good value based on its Price-To-Earnings Ratio (16x) compared to the estimated Fair Price-To-Earnings Ratio (29x).


Share Price vs Fair Value

What is the Fair Price of SAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SAN (€84.75) is trading below our estimate of fair value (€237.45)

Significantly Below Fair Value: SAN is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Sanofi forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


9.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SAN's forecast earnings growth (9.5% per year) is above the savings rate (0.3%).

Earnings vs Market: SAN's earnings (9.5% per year) are forecast to grow slower than the French market (11.5% per year).

High Growth Earnings: SAN's earnings are forecast to grow, but not significantly.

Revenue vs Market: SAN's revenue (4.3% per year) is forecast to grow slower than the French market (5.2% per year).

High Growth Revenue: SAN's revenue (4.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SAN's Return on Equity is forecast to be low in 3 years time (14%).


Discover growth companies

Past Performance

How has Sanofi performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


17.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SAN has high quality earnings.

Growing Profit Margin: SAN's current net profit margins (15.8%) are higher than last year (15.4%).


Past Earnings Growth Analysis

Earnings Trend: SAN's earnings have grown by 17.5% per year over the past 5 years.

Accelerating Growth: SAN's earnings growth over the past year (15%) is below its 5-year average (17.5% per year).

Earnings vs Industry: SAN earnings growth over the past year (15%) underperformed the Pharmaceuticals industry 15%.


Return on Equity

High ROE: SAN's Return on Equity (9.4%) is considered low.


Discover strong past performing companies

Financial Health

How is Sanofi's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: SAN's short term assets (€28.6B) exceed its short term liabilities (€22.1B).

Long Term Liabilities: SAN's short term assets (€28.6B) exceed its long term liabilities (€28.4B).


Debt to Equity History and Analysis

Debt Level: SAN's net debt to equity ratio (17%) is considered satisfactory.

Reducing Debt: SAN's debt to equity ratio has reduced from 31.8% to 26.7% over the past 5 years.

Debt Coverage: SAN's debt is well covered by operating cash flow (50.6%).

Interest Coverage: SAN's interest payments on its debt are well covered by EBIT (28.2x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Sanofi current dividend yield, its reliability and sustainability?

Dividend Score

5/6

Dividend Score 5/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


3.93%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: SAN's dividend (3.93%) is higher than the bottom 25% of dividend payers in the French market (1.67%).

High Dividend: SAN's dividend (3.93%) is low compared to the top 25% of dividend payers in the French market (5.26%).


Stability and Growth of Payments

Stable Dividend: SAN's dividends per share have been stable in the past 10 years.

Growing Dividend: SAN's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (62.8%), SAN's dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (54.9%), SAN's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.1yrs

Average management tenure


CEO

Paul Hudson (55 yo)

2.92yrs

Tenure

€10,982,970

Compensation

Mr. Paul Hudson has been Chief Executive Officer and Director at Sanofi since September 1, 2019. Mr. Hudson was Chief Executive Officer of Novartis Pharmaceuticals at Novartis AG since July 1, 2016 until J...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD11.34M) is above average for companies of similar size in the French market ($USD3.99M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SAN's management team is seasoned and experienced (7.1 years average tenure).


Board Members

Experienced Board: SAN's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sanofi's employee growth, exchange listings and data sources


Key Information

  • Name: Sanofi
  • Ticker: SAN
  • Exchange: ENXTPA
  • Founded: 1973
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €106.107b
  • Shares outstanding: 1.25b
  • Website: https://www.sanofi.com

Number of Employees


Location

  • Sanofi
  • 54, Rue La BoEtie
  • Paris
  • Ile-de-France
  • 75008
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/11 00:00
End of Day Share Price2022/08/11 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.